Thursday, September 16, 2010

U.S. Spine and Amedica - A White Wedding

Hey little sister what have you done
Hey little sister who's the only one
Hey little sister who's your superman
Hey little sister who's the one you want
Hey little sister shot gun
It's a nice day to start again, It's a nice day for a white wedding, It's a nice day to start againnnnnnnnnnnnnnnnnnnnnnnnn.

Yes fellow readers by the looks of things it may finally be true, U.S. Spine and Amedica are on the verge of merging, or will this be an acquisition. Why? I guess that $30 million that Amedica raised must be burning a whole in its pocket. But at a bargain basement price, how can one pass on this opportunity. TSB wants to know what our readers think?

Tuesday, September 14, 2010

Has NuVa Caught The Recession Flu?

It seems like chicken soup, nor even red beet borscht is going to help NuVasive's projections for fiscal 2010 . Today, the Wall Street Journal reported that Alex Lukianov has notified the Street that NuVa intends on cutting its forecast for sales growth and reductions to its top line 2010 guidance. Of course since there is no rhyme or reason to the market, NuVa's stock jumped 5% and closed at $33.13 per share. Tomorrow morning may be the time to sell off some of this stock, its hard to image that it will not take a hit when the market opens. TSB must admit, a little humble pie will go a long way for some of the people at NuVa. Seems like XLIF's shoulders have gotten tired of carrying the rest of the portfolio. I guess the Bear will have to limit himself to only one bottle of the 1998 Petrus.


Monday, September 13, 2010

The Thrilla in Manilla - Is Centinel Spine on The Ropes

This time there may be no Ferdinand Marcos around to divert attention from the financial turmoil that one of spine's self-endorsed up and coming companies could be experiencing. There may not be a reprieve. Where's Muhammed Ali when you need someone to perform the rope-a-dope? It seems that word on the Street is that Centinel Spine has been swinging away and hitting nothing but air. Could Centinel be experiencing a liquidity crisis? Could this crisis be a by product of legal pressures from the Paradigm BioDevices lawsuit, in addition to a supposedly huge decrease in revenue attributed to legitimate competition from companies with a comprehensive portfolio? If there is any truth to the word that employees have been asked to take a pass on their compensation for a couple of months, the question must be asked, whom is managing the money? Could the foxes be guarding the hen house?

Maybe some employees will come to their senses that they don't want to work for the man anymore. Why would anyone in their right mind need to put themselves in a position of vulnerability? Being someone else's employee is essentially putting oneself at the mercy of someone else's whim. Many times people that actually run companies don't get it. Many times TSB has posted that companies just don't get it. Values of candor, informality and innovation must be essential ingredients in today's workplace. People in any organization need to feel as though they have a say regardless of their rank. If there's any truth to this story, it will be interesting to see what the fall out will be. TSB wants to know what our readers have heard on the street?

Looks like we won't be drinking Cristal and smoking Cohiba's this year.

Friday, September 10, 2010

The Blue Velvets of the Spine Industry

It's a sunny, woodsy day in the spine world, so get those chainsaws out. This is Muscoloskeletal Man the musical voice of TSB. At the sound of the falling company, it's 9:30. There's a whole lotta wood out there, so let's get going. Where's Frank Booth when you need him? Unfortunately, he passed on to the afterlife.

Based on many rumors that have been circulating via e-mail, it seems that this may be the beginning of the end, or the last NASS for a few surrealistic companies that seem to be circling the drain. It seems that many start-up/early- growth stage companies are on a respirator ready for someone without enough of nerve to pull the plug on their suffering. So here are a list patients;

Applied Spine Technology: Posterior Dynamic Stabilization System, must we say anymore. How long can you keep riding Panjabi, at this point he may need back surgery.

Disc Motion Technology: Posterior Dynamic Stabilization System with Posterior Lumbar Disc, how much longer do you want to prolong the suffering? Get off the Amyl Nitrate.

U. S. Spine: I'm through attempting to make sense of anything that goes on at this company. Last time I saw Sendro and Blake they were Dancing with the Stars.

Impliant: I guess if someone could keep pouring money into this venture, it may have another six months. Hopefully if you resect enough of the posterior spine you will eventually eliminate pain.

Spine Wave: With any luck they may make it into 2011. The way these guys pay themselves, its a wonder there's any money left over for R&D. Crappy pedicle screw.

Eden Spine: Another Dynamic Stabilization System, no need to say anymore. In addition, we hear that an integral partner in bringing revenue is no longer at the Garden of Eden.

Yes fellow shoppers, there are deals to be had. It will depend on whether some of these people are willing to swallow their pride and ego's. The euphoric effect has had to wear off for many of these companies, its time to get back to reality, TSB wants to know what its readers think?




Wednesday, September 8, 2010

Will You Boycott Nass

Since Kanye West isn't available to upstage NASS' mantra that " their multidisciplinary history and ability to unite around core values (what's that) represent their greatest strength," TSB must ask our readers, isn't it time NASS gave something back to the people that have subsidized this five day bacchanalian orgy that is supposedly touted as a medical education meeting for spine specialists? This meeting has averaged 3,500 attendees annually over the last six years. What is entertaining to the naked eyes is that 97% of NASS attendees claim that they attend the technical exhibits. Unless you work for one of the superpowers of spine, outside of the first day, most days look like a post apocalyptic world where surgeons search for water to hydrate themselves from the night before.

NASS claims in their prospectus that 74% of attendees have the ability to authorize, specify or recommend products and services for purchase. Where? At a physician owned hospital? For a physician owned distributorship? Most attendees are not interested in seeing another commodity product. They are either selling their medical background to the highest bidder, or sponging off of some local rep so that they can pay for their lap dance at either Baby Dolls, the Diamond Club, Rachel's, Crystal Cabaret or the Doll House. What is it about tits and steak that attracts surgeons? You would think they never got any at home. Yet, the funniest commentary is that NASS actually propagandize that its attendees say that seeing a product or service at the technical exhibit is influential in decision making.

How ridiculous is it that NASS has the audacity to charge what it does, when it has been extorting money from vendors for the last twenty-five years? TSB has had the luxury of attending other industry related trade shows, never have I seen badges cost as much as they do at NASS. I guess someone has to subsidize Dr. Famous having a great time while they bitch and moan like little girls about how much money we make. You know maybe if they think that we make so much money, maybe they should pay us to listen to their insanity. TSB wants to know what our readers think? Yeah or Nay to this meeting this year?

Saturday, September 4, 2010

Weekend Op-Ed Piece

As the U.S. economy continues to struggle, the spine industry approaches the homestretch of fiscal 2010. In retrospect, 2010 may become known as the year of living dangerously. With much skepticism regarding the industry's overall health, one must ask the question, will the industry ever return to its old form, or, is the industry looking for that new technology or indication that will allow it to re-define who it is?

Regardless that a few companies have exhibited growth with existing platforms, success of a few may not be a viable prognosis for the many. Market trends that were once believed to be temporary, or cyclical in reacting to the economy, have become a permanent fixture within the industry. The longer these trends persist, inevitably they become the norm. So what are these trends and how will they affect the industry's future. As delivery of healthcare in the U.S. becomes financially prohibitive for the masses, as profit margins re-align themselves, as the insurance industry continues to looks for creative ways in managing risk, the industry will not be able to afford utilizing the same formula it has for the last decade. The margins in medical devices has been the envy of other industries . Though the industry is experiencing a re-alignment, the margins will still be good if not great compared to others. Unfortunately, as margins decrease, the industry as a whole will have to re-define its business model, in many respects those strategies are beginning to take place in many mid-cap companies that are looking at a direct sales force instead of independent distributors, in addition to decreasing commissions even more so than ever. So what are these trends and how will they affect us?

Unemployment: As unemployment yo-yo's at the current level, consumers are re-evaluating their personal healthcare needs. Depending on one's current state, this could be a positive or negative view. As higher deductibles are passed onto consumers by their employers and the insurance industry, consumers will become much more conservative in their utilization of healthcare, of course, unless there is an emergency, or, they have extinguished a conservative modality of treatment, meaning they just have not gone to see a physician. Consumers have already expressed concern that if they take time off for surgery, they may not have a job when they return, thus avoiding the risk for unemployment. The cost of COBRA is a tremendous financial onus for the unemployed. As COBRA coverage expires, medical markets experience a decline in revenue. Desperate times, may call for desperate measures. As government continues to focus on the escalating cost of delivering healthcare, consumers are beginning to exhibit fiscal constraint not only in the way they manage their finances, but also in the way that they are managing themselves. Special interest groups complain about big government, yet, if the government did not step in during the last few years the financial ramifications for the industry could have been much worse than they were. Single digit growth and describing the market as flat, has become the industry's new mantra.

Pricing: Hospitals and purchasing organizations are placing tremendous pressure on the medical device industry to discount its pricing. The genie was out of the bottle a long time ago, and the industry has no one else to blame except itself. As hospital margins decline, companies are already succumbing to the demands for lower pricing in order to preserve current market share. Thin is in, and single digit growth may be with the industry for years to come. The strong will survive, the weak shall perish. A greater onus will be placed on the industry to figure out how to manufacture products in a cheaper, faster, more efficient way, without compromising quality than already exists. This will mean exporting manufacturing and more jobs overseas, or potentially looking for new frontiers. It could be India, China, or Indonesia. In many respects, maybe these countries will become better at making implants that the U.S. and beat us at our own game. In addition, premium pricing will be predicated on new and innovative technologies that truly affect clinical outcomes. The days of developing a product first, and then looking for a clinical indication are gone, witnessed by the current state. Pricing and profit will be a temporary windfall. The industry cannot continue charging a premium in a commoditized market? Until there is contraction in the number of existing spine companies selling "me too" products, a saturated market will not be able to sustain itself in this economy. If the reader does not believe this, just look back historically at other industries. Today, many of the smaller companies survive by becoming involved with physician owned distributors, physician investors, or physician owned hospitals, but even those business models are under tremendous scrutiny. As more and more physician practices become integrated with hospitals, or are owners of a hospital, or they own physician owned distributorships, the incentive is and will be to drive down pricing. This will affect the industry's ability to charge a premium for its products considering that it is estimated that 20-25% of a hospitals budget is dedicated to the purchase of medical devices.

The Gipper once said, tighten your belts because the industry is in for a bit of a ride. Trying to make sense of it all, I can see that at times it makes no sense at all. So remember the lyrics from Stealers Wheel, "clowns to the left of me, jokers to the right, here I am stuck in the middle with you. TSB wants to know what our readers think?





Thursday, September 2, 2010

Dog Daze Afternoon

Considering that these are the dog daze of summer, there has been much underground chatter heard on the street. For starters, TSB has heard that there has been some internal movement at ATEC. Difficult to tell whether it was an internal cleanse, or just someone's take on the situation. Not only is ATEC facing Class Action Lawsuits, but the FDA has been crawling around their orifice, or was that office.

A source confirmed today that Amedica has definitely dropped its pursuit in acquiring U.S. Spine as a result of too much baggage, in terms of debt. The asking price was probably totally unrealistic. I guess this opens up the potential for another early-growth stage company to enter the "I want to be acquired" race. TSB envisions a company that generates an estimated $8-$10 million in revenue, being offered 1.5X for their company. $12 - $15 million dollars sounds right. You know what Steve Miller sang, "take the money and run." TSB wonders whom our readers think would be a viable acquisition? If I were Amedica I would continue to focus on the recon market with their self=proclaimed super duper material, and sell off whatever they have in their spine portfolio.

Seems like there are some companies that are hanging on a shoes string. Applied Spine may be in some trouble along with anyone else looking to bring a dynamic stabilization system to the market. What ever happened to Eden Spine? Are they generating any revenue? Lastly, TSB finds it interesting that Stem Cells seem to be the topic du jour, most days on the OTW website, You know what they say about those financial people, they sure know how to be market makers, even if there is more fiction than truth. Is NuVasive heading for another bout with the insurance industry regarding XLIF? TSB's been watching that stock, and maybe there is some truth to the scuttlebutt on the Street.

As we approach the Labor Day Weekend, remember to fire up the Barbie, crack open a cold one and sing in unison, make the world go away. TSB wants to know what our readers think?